Evidence map›Paper›PMID 31577704›Full record

SynthesisMedicine2019

Quality assessment of kidney cancer clinical practice guidelines using AGREE II instrument: A critical review.

XiaoFeng Hou, Meixuan Li, Wenbo He, Meng Wang, Peijing Yan, Caiwen Han, Huijuan Li, Liujiao Cao, Biao Zhou, Zhenxing Lu and 4 more

Abstract readSystematic Review
In one paragraph

Synthesis in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

XiaoFeng HouGansu Provincial Cancer Hospital.
Meixuan LiSchool of Public Health, Lanzhou University.
Wenbo HeSchool of Public Health, Lanzhou University.
Meng WangSchool of Public Health, Lanzhou University.
Peijing YanInstitute of Clinical Research and Evidence Based Medicine, The Gansu Provincial Hospital.
Caiwen HanInstitute of Clinical Research and Evidence Based Medicine, The Gansu Provincial Hospital.
Huijuan LiSchool of Public Health, Lanzhou University.
Liujiao CaoSchool of Public Health, Lanzhou University.
Biao ZhouThe First Clinical Medical College, Lanzhou University.
Zhenxing LuThe First Clinical Medical College, Lanzhou University.
Bibo JiaGansu Provincial Cancer Hospital.
Jing LiGansu Provincial Cancer Hospital.
Xu HuiGansu Provincial Cancer Hospital.
Yunxia LiDepartment of Oncology, Gansu Gem Flower Hospital, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvidence-based guidelines are expected to provide clinicians with explicit recommendations on how to manage health conditions and bridge the gap between research and clinical practice. However, the existing practice guidelines(CPGs) vary in quality. This study aimed to evaluate the quality of CPGs of kidney cancer.

methodsWe systematically searched PubMed, Embase, China Biology Medicine disc, and relevant guideline websites from their inception to April, 2018. We identified CGPs that provided recommendations on kidney cancer; 4 independent reviewers assessed the eligible CGPs using the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument. The consistency of evaluations was calculated using intraclass correlation coefficients (ICC).

resultsA total of 13 kidney cancer CGPs were included. The mean scores for each AGREEII domain were as follows: scope and purpose-76.9%; clarity and presentation-76.4%; stakeholder involvement-62.8%; rigor of development-58.7%; editorial independence-53.7%; and applicability-49.4%. Two CPGs were rated as "recommended"; 8 as "recommended with modifications"; and 3 as "not recommended." Seven grading systems were used by kidney cancer CGPs to rate the level of evidence and the strength of recommendation.

conclusionsOverall, the quality of CPGs of kidney cancer is suboptimal. AGREE II assessment results highlight the need to improve CPG development processes, editorial independence, and applicability in this field. It is necessary to develop a standardized grading system to provide clear information about the level of evidence and the strength of recommendation for future kidney cancer CGPs.

Indexed as

HumansKidney NeoplasmsPractice Guidelines as Topic

Identifiers

PMID31577704
PMCPMC6783175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.